Recursion Pharmaceuticals... (RXRX)
Recursion Pharmaceuticals Statistics
Share Statistics
Recursion Pharmaceuticals has 395.07M shares outstanding. The number of shares has increased by 71.69% in one year.
| Shares Outstanding | 395.07M |
| Shares Change (YoY) | 71.69% |
| Shares Change (QoQ) | 2.96% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 305.72M |
| Failed to Deliver (FTD) Shares | 27.66K |
| FTD / Avg. Volume | 0.12% |
Short Selling Information
The latest short interest is 67.86M, so 17.68% of the outstanding shares have been sold short.
| Short Interest | 67.86M |
| Short % of Shares Out | 17.68% |
| Short % of Float | 20.96% |
| Short Ratio (days to cover) | 4.15 |
Valuation Ratios
The PE ratio is -4 and the forward PE ratio is -4.64. Recursion Pharmaceuticals's PEG ratio is -0.57.
| PE Ratio | -4 |
| Forward PE | -4.64 |
| PS Ratio | 31.5 |
| Forward PS | 9.8 |
| PB Ratio | 1.79 |
| P/FCF Ratio | -4.97 |
| PEG Ratio | -0.57 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Recursion Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.81, with a Debt / Equity ratio of 0.1.
| Current Ratio | 3.81 |
| Quick Ratio | 3.81 |
| Debt / Equity | 0.1 |
| Debt / EBITDA | -0.25 |
| Debt / FCF | -0.29 |
| Interest Coverage | -304.71 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $73.55K |
| Profits Per Employee | $-579.58K |
| Employee Count | 800 |
| Asset Turnover | 0.04 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -1.13M |
| Effective Tax Rate | 0.24% |
Stock Price Statistics
The stock price has increased by -44.79% in the last 52 weeks. The beta is 0.99, so Recursion Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.99 |
| 52-Week Price Change | -44.79% |
| 50-Day Moving Average | 7.22 |
| 200-Day Moving Average | 7.11 |
| Relative Strength Index (RSI) | 31.08 |
| Average Volume (20 Days) | 23.31M |
Income Statement
In the last 12 months, Recursion Pharmaceuticals had revenue of 58.84M and earned -463.66M in profits. Earnings per share was -1.69.
| Revenue | 58.84M |
| Gross Profit | 13.6M |
| Operating Income | -479M |
| Net Income | -463.66M |
| EBITDA | -426.72M |
| EBIT | -463.22M |
| Earnings Per Share (EPS) | -1.69 |
Balance Sheet
The company has 594.35M in cash and 108.49M in debt, giving a net cash position of 485.86M.
| Cash & Cash Equivalents | 594.35M |
| Total Debt | 108.49M |
| Net Cash | 485.86M |
| Retained Earnings | -1.43B |
| Total Assets | 1.45B |
| Working Capital | 526.8M |
Cash Flow
In the last 12 months, operating cash flow was -359.17M and capital expenditures -13.7M, giving a free cash flow of -372.87M.
| Operating Cash Flow | -359.17M |
| Capital Expenditures | -13.7M |
| Free Cash Flow | -372.87M |
| FCF Per Share | -1.36 |
Margins
Gross margin is 23.12%, with operating and profit margins of -814.09% and -788.02%.
| Gross Margin | 23.12% |
| Operating Margin | -814.09% |
| Pretax Margin | -789.93% |
| Profit Margin | -788.02% |
| EBITDA Margin | -725.24% |
| EBIT Margin | -814.09% |
| FCF Margin | -633.71% |
Dividends & Yields
RXRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for RXRX is $8, which is 66% higher than the current price. The consensus rating is "Hold".
| Price Target | $8 |
| Price Target Difference | 66% |
| Analyst Consensus | Hold |
| Analyst Count | 4 |
Scores
| Altman Z-Score | 0.93 |
| Piotroski F-Score | 2 |